Summary of meta-analyses comparing various durations of DAPT after coronary stent insertion
| OUTCOMES | STUDY-DEFINED LONG (12, 18, 24, 30, AND 36 MO) VS SHORT (3, 6, AND 12 MO) DAPT24–31 | EXTENDED (18, 30, AND 36 MO) VS STANDARD (12 MO) DAPT24–28,30,31 | ABBREVIATED (3 AND 6 MO) VS STANDARD (12 AND 24 MO) DAPT24–28,30,31 |
|---|---|---|---|
| Benefit | |||
| • MI | ARR = 0.7%–1%; NNT = 100–143 | ARR = 1%–1.4%; NNT = 71–100 | NS |
| • Stent thrombosis | ARR = 0.4%; NNT = 250 | ARR = 0.6%–0.7%; NNT = 143–167 | NS |
| Harm | |||
| • All-cause mortality | ARI = 0.3%; NNH = 334* (3 of 7 meta-analyses were NS) | ARI = 0.4%; NNH = 250* (3 of 8 meta-analyses were NS) | NS |
| • Major bleeding | ARI = 0.5%–0.8%; NNH = 143–200 | ARI = 0.7%–1.1%; NNH = 91–143 | ARI = 0.2%–0.4%; NNH = 250–500 |
| No benefit or harm | |||
| • Cardiovascular mortality | NS | NS | NS |
| • Stroke | NS | NS | NS |
ARI—absolute risk increase, ARR—absolute risk reduction, DAPT—dual antiplatelet therapy, MI—myocardial infarction, NNH—number needed to harm, NNT—number needed to treat, NS—not statistically significant
↵* Increased all-cause mortality risk was not found in all meta-analyses comparing different durations of DAPT.